1) irinotecan
依立替康
1.
Combination chemotherapy with irinotecan and cisplatin as second-line treatment for small cell lung cancer;
依立替康联合顺铂二线治疗小细胞肺癌
2.
A randomized controlled clinical trial on irinotecan/cisplatin versus gemcitabine/cisplatin as the first-line treatment in advanced non-small cell lung cancer;
依立替康/顺铂与吉西他滨/顺铂方案一线治疗晚期非小细胞肺癌随机对照临床研究
3.
Irinotecan/cisplatin versus Etoposide/cisplatin for Patients with Extensive Stage Small Cell Lung Cancer:A Systematic Review
依立替康联合顺铂与足叶乙甙联合顺铂治疗广泛期小细胞肺癌的系统评价
2) Irinotecan
伊立替康
1.
Advancement in the Synthesis and Clinical Application of the New Anticancer Drug Irinotecan;
抗肿瘤新药伊立替康的合成和应用进展
2.
The adverse reactions and management of irinotecan;
盐酸伊立替康的不良反应及其预防处理
3.
Short-term effects of irinotecan plus capecitabine as first-line treatment for advanced colorectal carcinoma;
伊立替康联合卡培他滨—线治疗晚期结直肠癌的近期疗效
3) Irinotecan hydrochloride
盐酸依列替康
4) Irinotecan hydrochloride
盐酸伊立替康
1.
Preparation and quality evaluation of irinotecan hydrochloride lyophilized liposomes
盐酸伊立替康脂质体冻干粉针的制备及其质量评价
2.
Preparation of irinotecan hydrochloride containing liposomes by ammonium sulfate gradient method and its release in vitro
硫酸铵梯度法制备盐酸伊立替康脂质体及体外释放的研究
3.
METHODS:Irinotecan hydrochloride liposome was prepared by ammonium sulfate gradient method.
目的:制备盐酸伊立替康脂质体并考察其体外释药特性。
5) Irinotecan(CPT-11)
伊立替康(CPT-11)
6) irinotecan/therapeutic use
伊立替康/治疗应用
补充资料：依立雄胺
分子式：暂无
分子量：暂无
CAS号：119169-78-7
性质：暂无
制备方法：暂无
用途：睾酮还原酶抑制剂。
分子量：暂无
CAS号：119169-78-7
性质：暂无
制备方法：暂无
用途：睾酮还原酶抑制剂。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条